Skip to content

Study to evaluate the safety and feasibility of the STENTYS Balloon Delivery System (STENTYS-BDS).

Study to evaluate the safety and feasibility of the STENTYS Balloon Delivery System (STENTYS-BDS). - SETUP

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON41177
Enrollment
20
Registered
2014-07-22
Start date
2014-08-27
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary artery stenosis coronary atherosclerosis

Interventions

None listed

Sponsors

STENTYS
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Age between 18 years and 80 years. 2. Patients with an indication to receive a STENTYS-SES according to the IFU.* 3. Signed Informed Consent. 4. Reference Vessel Diameter >2.5mm and

Exclusion criteria

Exclusion criteria: Clinical: 1. Pregnant or breastfeeding woman or woman in fertile period not taking adequate contraceptives 2. Currently enrolled in another investigational device or drug study that has not completed the primary endpoint or that clinically interferes with the current study endpoints. 3. Patients on anticoagulation therapy (Coumadin). 4. Known intolerance to aspirin, clopidogrel, heparin, stainless steel, sirolimus, contrast material. 5. Known thrombocytopenia (PLT30% by visual assessment 13. Staged procedure is planned within 30 days* 14. Target lesion is a chronic total occlusion 15. Perforated vessels evidenced by extravagation of contrast media;* Treatment of other lesions during the same procedure in target- and non-target vessel is allowed

Design outcomes

Primary

MeasureTime frame
Technical success, defined as the ability to cross with the device and deploy the stent as intended at the target lesion.

Secondary

MeasureTime frame
Geographical miss, defined as the entire length of the stenotic segment not fully covered by the total length of the stent. 2. Angiographic success, defined as final result

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)